R&D
Therapeutics
Microbiome Therapeutics Pipeline - Allergic Diseases
Pipeline
Indication
Discovery
Preclinical
Clinical Development
Phase1
Phase2
Phase3
LABTHERA-004
Allergic Diseases
Allergic rhinitis is a common allergic condition characterized by immune hypersensitivity of the nasal mucosa.
Its global prevalence continues to rise, driven by changes in living environments and increasing environmental pollution.
Its global prevalence continues to rise, driven by changes in living environments and increasing environmental pollution.
The gut microbiome plays a critical role in regulating and activating the immune system.
Disruption of microbiome balance can impair immune and inflammatory control, alter host–microbe interactions, and contribute to chronic inflammatory diseases, including allergic asthma and allergic rhinitis. Growing evidence suggests that gut microbiome dysbiosis is closely associated with both the development and severity of allergic rhinitis.
Disruption of microbiome balance can impair immune and inflammatory control, alter host–microbe interactions, and contribute to chronic inflammatory diseases, including allergic asthma and allergic rhinitis. Growing evidence suggests that gut microbiome dysbiosis is closely associated with both the development and severity of allergic rhinitis.
ATOGEN is developing differentiated microbiome-based therapeutics for allergic rhinitis by identifying proprietary strains from its internal strain library that reduce OVA-specific IgE levels and Th2 cytokine responses.
Microbiome-based therapies offer the potential for safe use as monotherapy or in combination with existing treatments, providing a disease-relevant, multi-mechanistic approach to allergic rhinitis without the burden of systemic side effects.